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1. Introduction
Sexually transmitted infections (STIs) are caused by the transmission of more than 30 vari-
ous bacteria, viruses, and parasites from one individual to another [1, 2]. Transmission can 
occur in different ways such as vaginal, anal, and oral sexual contact. Besides, they can also 
be transmitted from pregnant women to their fetus during pregnancy, during birth, through 
breast‐feeding, and by parenteral routes [1, 3].
STIs are still a serious public health problem despite efforts and precautions worldwide. 
According to the World Health Organization (WHO), it is estimated that more than 1 mil-
lion new STIs occur everyday globally. In the United States (US), the total number of STIs 
is around 110 million per annum and 20 million of these cases are newly acquired [4]. In 
England, the rates of most of the STIs had rapidly increased from the late 1990s to 2012 and 
approximately 500,000 STI diagnoses are now made annually [5]. In 2012, more than 40,000 
new cases of HIV/AIDS and more than 1.5 million cases of syphilis, gonorrhea, and hepatitis 
B were reported in China [6]. Approximately 250 million women are affected by gonorrhea, 
chlamydia, syphilis, or trichomoniasis per year [7].
1.1. Sexually transmitted bacterial infections
Chlamydia trachomatis infections are the most reported bacterial STI in the US [8]. In the United 
Kingdom (UK), although it is the most commonly diagnosed bacterial STI, it is thought that 
there are many chlamydial infections that cannot be diagnosed and treated. Therefore, its 
frequency is not clearly known, but there were approximately 240,000 diagnosis in 2012 [5]. A 
study reported that the overall prevalence of C. trachomatis infection was 11% with the high-
est prevalence observed in women between 16 and 20 years of age in Brazil [9]. Because most 
cases are asymptomatic, the detection of the infection depends on the screening [10].
© 2017 The Author(s). Licensee InTech. This chapt r is distributed under the terms of the Creative Comm s
Attribution L cense (http://creativecommons. /licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
Gonorrhea caused by Neisseria gonorrhoeae is usually characterized by urethritis in men and 
cervicitis in women [11]. N. gonorrhea is the second most common reported bacterial STI in the 
US [12]. More than 350,000 cases of gonorrhea were reported in the US in 2014.
Syphilis caused by Treponema pallidum is one of the bacterial STIs that has been known for 
centuries [13]. Globally, 12 million new cases are estimated annually. Most of the new cases 
are probably in Southern Asia and Sub‐Saharan Africa according to WHO [14]. The number 
of syphilis cases reported was about 46,000 in the US in 2010 [15].
Chancroid caused by Haemophilus ducreyi is more common in Africa, Asia, and Latin America. 
But recently, this infection is less common both in developed and in less‐developed countries. 
Due to diagnostic challenges, the exact frequency is not clearly known [16]. It is more com-
mon in men than in women and male circumcision is thought to reduce the risk of transmis-
sion of infection [17].
Donovanosis (also known as granuloma inguinale) caused by Klebsiella granulomatis (formerly 
known as Calymmatobacterium granulomatis) is less common disease that occurs with genital 
ulceration.
Lymphogranuloma venereum (LGV) is caused by C. trachomatis serotype L1, L2, and L3. 
Although the disease is endemic in East and West Africa, India, Southeast Asia, and the 
Caribbean, it is less common in Europe [18]. Also, LGV is traditionally described as “a spo-
radic disease” in North America, Europe, and Oceania, but highly prevalent in parts of Africa, 
Asia, and South America [19, 20].
1.2. Sexually transmitted viral infections
Human papilloma virus (HPV) is the most common STI in the US [21]. It is estimated that 14 mil-
lion people are infected with HPV annually [22]. Although there are over 100 strains of HPV, 
only about 40 HPV strains that cause benign or malign lesions are detected on the surface of 
anogenital skin. HPV strains are divided into two categories: high‐risk strains and low‐risk 
strains. High‐risk strains, especially, HPV types 16 and 18, are responsible for malignant lesions 
such as cervical, penile, vulvar, vaginal, anal and oropharyngeal cancers, and premalignant 
lesions such as cervical dysplasia. Low‐risk strains are responsible for benign lesions such as 
anogenital warts, benign or low‐grade cellular changes, and recurrent respiratory papilloma-
tosis (RRP) [21].
Genital herpes caused by the Herpes simplex virus (HSV) is the most common disease with 
genital ulceration worldwide. To date, it is estimated that about 50 million people are infected 
with HSV‐2 in the US and it is thought that there are over 750,000 new cases each year [23]. 
HSV is divided into two subtypes: HSV‐1 and HSV‐2. The main cause of genital herpes is 
HSV‐2; but in recent years, the frequency of genital diseases caused by HSV‐1 has increased 
due to increasingly common oral sex among adolescents and adults [24].
Human immunodeficiency virus (HIV)‐1 may transmit vertically and through blood in addition 
to sexual intercourse. About 78 million people have suffered from HIV and 39 million deaths 
have occurred since the beginning of this epidemic. While the global prevalence of HIV was 
31 million in 2002, at the end of the next 10 years, this number exceeded 35 million [25].
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While Hepatitis C virus (HCV) is transmitted primarily through blood exposure, it has glob-
ally emerged as a STD among HIV‐infected men that have sex with men for the last 20 years 
[26]. Moreover, illicit drug use, unprotected anal intercourse, potentially traumatic sexual 
practices such as first sexual experience and inappropriate and common use of sex toys are 
the other factors facilitating transmission [19].
1.3. Sexually transmitted parasitic infections
Trichomoniasis caused by Trichomonas vaginalis that is highly prevalent in the US affects 11 
million people per year. Approximately 62% of this figure is women. Trichomoniasis is com-
monly asymptomatic (70–100% of male population and 35–85% of female population) and 
transmission between partners easily occurs [27, 28].
2. Management of STIs
While STIs continue to be a general public health problem worldwide, unfortunately, there is 
no globally established STI surveillance system. While passive STI surveillance is performed 
using reports from STI control programs and public health laboratories in some countries 
such as the US, Canada, and Australia, there are limited published STI surveillance reports 
from Middle East and Northern Africa and Sub‐Saharan Africa [29].
2.1. STI preventive counseling
In preventive counseling, interactive individual communication between health‐care pro-
vider and patient is very important. Providers should also inform to their patients about 
risk‐reduction strategies such as abstinence, condom use, limiting the number of sex part-
ners, modifying sexual practices, and vaccination. High‐risk behaviors are defined by the US 
Preventive Services Task Force (USPSTF) as having multiple current partners, having a new 
partner, using condom inconsistently, having sex while under the influence of alcohol or 
drugs, or exchanging sex for money or drugs [30, 31].
2.2. Sexual abstinence
One of the most reliable ways to prevent STIs is to abstain from oral, vaginal, and anal sexual 
intercourse or to have a long‐term relationship with an uninfected partner. If any of the part-
ners are being treated, couples should be informed that they should avoid sexual intercourse 
until the treatment is completed [30].
2.3. Vaccination
To prevent infectious diseases, vaccination seems to be the best strategy for long‐term protec-
tion [32]. Although preexposure vaccination is a very effective method for preventing trans-
mission of STIs, vaccines have not yet been developed except for three viral diseases including 
HPV, hepatitis A, and hepatitis B [30, 31].
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There are three different prophylactic HPV vaccines approved by the Food and Drug 
Administration (FDA): Cervarix (GlaxoSmithKline, NY), Gardasil (Merck&Co, Kenilworth, NJ), 
and Gardasil‐9 (Merck&Co) [25, 33]. The first generation HPV vaccines (bivalent Cervarix and 
quadrivalent Gardasil) are licensed in more than 100 countries since 2006. The second gen-
eration HPV vaccine (9vHPV vaccine) was licensed in the US in December 2014 [34]. Both 
males and females can be vaccinated with HPV vaccines according to Advisory Committee on 
Immunization Practices (ACIP). Vaccine can be applied from 9 years old. Furthermore, vac-
cination is recommended for females aged 13–21 years and for males 13–21 years who have 
not been vaccinated previously or who have not completed the three‐dose series. Any of the 
three different vaccines is recommended for females, although either Gardasil or Gardasil‐9 
is recommended for males [22]. Quadrivalent HPV vaccine prevents both anal intraepithelial 
neoplasia (AIN) and anogenital warts in men [35].
Hepatitis B vaccine is recommended for everyone who has a risk of transmission of STIs 
[30, 36].
Hepatitis A vaccine, the same as hepatitis B vaccine, is recommended for men who have sex 
with men (MSM), injection drug users, and HIV‐infected persons who have not yet been 
infected with hepatitis A virus [30].
2.4. Using condom and other barrier methods
Male and female condoms play an important role both in preventing pregnancy and in reduc-
ing the risk of transmission of infections including HPV, HIV, HSV, gonorrhea, chlamydia, 
syphilis, hepatitis B, hepatitis C, and Trichomonas. For these purposes, condoms can be used 
alone or in combination with other contraceptive methods [7, 30]. Using male latex condoms 
recommended by Centers for Disease Control and Prevention (CDC) is quite important to 
protect HCV transmission, because there is no vaccine for hepatitis C infection [26]. Only one 
vaginally inserted condom is approved in the US. But, research on new vaginal female con-
dom models like Origami female condom is still ongoing [7].
2.5. Male circumcision
Male circumcision may reduce the risk of transmission of HIV and some STIs in heterosexual 
men and is recommended for preventing heterosexually acquired HIV infection by the WHO 
and the Joint United Nations Program on HIV/AIDS (UNAIDS) [30]. Male circumcision also 
increases the tendency to genital discharge syndrome. With contradictory results, the efficacy 
of male circumcision in preventing STIs in the general population has not been clearly dem-
onstrated [37].
2.6. Postexposure and preexposure prophylaxis
Postexposure prophylaxis (PEP) and preexposure prophylaxis (PrEP) of the uninfected part-
ner are the other preventive strategies [7]. Genital hygiene methods (e.g., vaginal washing) 
after sexual exposure should not be recommended as preventive methods [30]. In addition, 
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the reasons such as a clinician visit and medication initiation within 72 h after exposure limit 
the use of PEP. But on the contrary, oral PrEP approved by the FDA is an effective HIV pre-
vention tool [7]. With the implementation of PrEP and other preventive strategies, it has been 
observed that there is a significant reduction in the number of newly diagnosed HIV cases 
that occur among MSM in the US each year [38, 39].
2.7. Partner management
The first step of partner management should be partner notification. Knowing the sex‐ and 
needle‐sharing partners of infected persons allow to communicate with them directly or 
through state and local health departments. Thus, health counseling can be provided to the 
partners at risk and may be encouraged for medical evaluation and treatment in health care 
services [30].
3. Risk factors for STIs
The distribution of STIs in the population varies depending on different factors includ-
ing individuals, social, and structural factors [6]. All sexually active people including het-
erosexual persons, MSM, and women who have sex with women are at risk. Most of the 
STIs are transmitted more easily from a man to a woman than from a woman to a man. 
Adolescents and young adults are the age groups at greatest risk of acquiring of STIs due 
to some reasons such as having multiple sex partners, unprotected sexual intercourse, and 
substance use [3].
Younger age is a significant risk factor for STIs [6]. Young people, especially aged 15–24 years, 
have a large number of sexual partners than older adults and these young individuals do not 
have the habits of using regular condom during sexual intercourse. In women, STIs, mostly 
for chlamydia, genital warts, and gonorrhea, are usually seen from the age of 15, peak at 19 
years, and begin to decline from the first year of the third decade [5].
Concurrent of HIV/STIs is significant risk factor for acquiring other STIs [5]. Some studies 
have shown that the transmission rates of HCV as a STI is very low among heterosexual 
couples. Similarly, the rate of sexually transmitted HCV infection in HIV‐negative MSM 
is low [40].
Socioeconomic status such as level of education, occupation, and number of sexual partners 
of the individual is the other risk factor for STIs. Individuals with low level of education, 
especially drug users, are at high risk for HIV. The frequency of HIV/STIs has increased in 
some occupations such as long‐distance truck drivers and sex workers. Due to possibility of 
multiple sex partners, STIs are frequently seen in people and regions with high‐income levels 
[5]. While more than half of four curable STIs including chlamydia, gonorrhea, trichomo-
niasis, and syphilis occurred in upper‐middle income countries, other remaining infections 
occurred in lower‐middle income countries with 23%, low‐income countries with 12%, and 
high‐income countries with 9%, respectively [2].
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Some behaviors including having multiple sex partners, sexual intercourse without condom 
use, illicit drug use, sharing of injected equipment’s, and alcohol use are generally associated 
with a higher prevalence of HIV/STIs [5]. High‐risk behaviors such as serosorting and chem-
sex may increase the rate of sexually transmitted HCV [40].
3.1. Complications and morbidities of STIs
Most of the STIs are asymptomatic. For this reason, there may be unnoticed, undetected, and 
untreated cases and serious complications can be seen in these cases [1, 36]. Possible compli-
cations are shown in Table 1.
3.2. Screening of STIs
As noted below, the screening of certain groups is urgently recommended:
1. Everyone between the ages of 13 and 64 years should be tested at least once for HIV.
2. Sexually active females up to 24 years should routinely be screened for chlamydia every year.
3. Nonpregnant women at higher risk of infection should be screened for gonorrhea and 
syphilis.
4. Pregnant women, regardless of risk, should be screened for chlamydia, hepatitis B, HIV, 
and syphilis; pregnant women at higher risk of infection should also be screened for gon-
orrhea and hepatitis C.










• Cardiovascular and neurological damage
• Fetal and neonatal morbidity and mortality (stillbirths, neonatal death, preterm or low‐birth‐weight baby, 
blindness)
• Aseptic meningitis
• Preterm rupture of membranes during pregnancy
Table 1. Possible complications caused by STIs [1, 5, 28, 41–43].
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6.  MSM should be screened at least annually for HIV and syphilis and undergo a test for 
urethral chlamydia and gonorrhea infection. Men who participate in receptive anal inter-
course should be tested for rectal chlamydia and gonorrhea and, in those who participate 
in oral intercourse, for pharyngeal gonorrhea [31].
4. STIs in children
STIs can also be seen in children. As transmission may be in utero, it may occur during deliv-
ery or after contact with contaminated devices and infected persons. But it should always be 
kept in mind that there may be sexual abuse [44]. Victims of sexual abuse were reported as 1.8 
per 1000 children in 2006 [45].
In asymptomatic prepubertal children, STIs screening for all organisms from all sites is not 
recommended by American Academy of Pediatrics (AAP) guidelines. However, the clinician 
should consider the following situations when deciding whether to screen or not:
1. History of penetration or evidence of recent or healed penetrative injury to the genitals, 
anus, or oropharynx.
2. Abuse by a stranger.
3. Abuse by a perpetrator known to be infected with an STI or at high risk of STIs (intrave-
nous drug users, MSM, or people with multiple sexual partners).
4. Sibling or other relative in the household with an STI.
5. Residence in an area with a high rate of STI in the community.
6. Signs or symptoms of STIs.
7. Already diagnosed with one STI (and therefore should be screened for other STIs) [45].
Child sexual assault (CSA) survivors may have a risky sexual life in their future. Therefore, 
HPV vaccination for CSA survivors aged 9–26 years for females and aged 9–21 years for males 
is recommended in accordance with ACIP [45].
5. Conclusion
At present, STIs are not fully under control with current strategies and continue to cause seri-
ous public health problems. From early ages, individuals, especially those at high risk, should 
be informed about STIs and the methods of prevention from these infections. Health care pro-
viders should communicate individually with infected individuals and their partners. Proper 
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screening of high‐risk individuals is crucial for early detection and treatment. Considered the 
data in recent years, it seems likely that the addition of vaccines that are proven efficacious to 
national vaccination programs of all countries would be beneficial.
Author details
Gürkan Yardımcı1*, Server Serdaroğlu2 and Zekayi Kutlubay2
*Address all correspondence to: dr.gurkanyardimci@gmail.com
1 Health Care Practice & Research Center, Esenler Hospital, Istanbul Medipol University, 
Istanbul, Turkey
2 Department of Dermatology, Cerrahpasa Medical Faculty, Istanbul University, Istanbul, 
Turkey
References
[1] Wagenlehner FM, Brockmeyer NH, Discher T, Friese K, Wichelhaus TA. The presenta-
tion, diagnosis, and treatment of sexually transmitted infections. Deutsches Ärzteblatt 
International. 2016;113:11‐22. DOI: 10.3238/arztebl.2016.0011
[2] Newman L, Rowley J, Vander Hoorn S, Wijesooriya NS, Unemo M, Low N, et al. Global 
estimates of the prevalence and incidence of four curable sexually transmitted infections 
in 2012 based on systematic review and global reporting. PLoS One. 2015;10:e0143304. 
DOI: 10.1371/journal.pone.0143304
[3] Eng TR, Butler WT, editors. Institute of medicine (us) committee on prevention and 
control of sexually transmitted diseases. The Hidden Epidemic: Confronting Sexually 
Transmitted Diseases: Summary. Washington (DC): National Academies Press (US); 
1997
[4] Lupfer C, Anand PK. Integrating inflammasome signaling in sexually transmitted infec-
tions. Trends in Immunology. 2016;37:703‐714. DOI: 10.1016/j.it.2016.08.004
[5] Hughes G, Field N. The epidemiology of sexually transmitted infections in the UK: 
Impact of behavior, services and interventions. Future Microbiology. 2015;10:35‐51. 
DOI: 10.2217/fmb.14.110
[6] Zhao Y, Luo T, Tucker JD, Wong WC. Risk factors of HIV and other sexually transmitted 
infections in China: A systematic review of reviews. PLoS One. 2015;10:e0140426. DOI: 
10.1371/journal.pone.0140426
[7] Seidman D, Hemmerling A, Smith‐McCune K. Emerging technologies to prevent 
pregnancy and sexually transmitted infections in women. Seminars in Reproductive 
Medicine. 2016;34:159‐167. DOI: 10.1055/s‐0036‐1571436
Fundamentals of Sexually Transmitted Infections10
[8] Lane AB, Decker CF. Chlamydia trachomatis infections. Disease‐a‐month. 2016;62:269‐
273. DOI: 10.1016/j.disamonth.2016.03.010
[9] Brasiliense DM, Borges Bdo N, Ferreira WA. Genotyping and prevalence of Chlamydia 
trachomatis infection among women in Belém, Pará, northern Brazil. The Journal of 
Infection in Developing Countries. 2016;10:134‐137. DOI: 10.3855/jidc.6474
[10] Geisler WM. Diagnosis and management of uncomplicated Chlamydia trachomatis 
infections in adolescents and adults: Summary of evidence reviewed for the 2015 centers 
for disease control and prevention sexually transmitted diseases treatment guidelines. 
Clinical Infectious Diseases. 2015;61:S774‐S784. DOI: 10.1093/cid/civ694
[11] Morgan MK, Decker CF. Gonorrhea. Disease‐a‐month. 2016;62:260‐268. DOI: 10.1016/j.
disamonth.2016.03.009
[12] Lancaster JW, Mahoney MV, Mandal S, Lawrence KR. Update on treatment options for 
gonococcal infections. Pharmacotherapy. 2015;35:856‐868. DOI: 10.1002/phar.1627
[13] Eickhoff CA, Decker CF. Syphilis. Disease‐a‐month. 2016;62:280‐286. DOI: 10.1016/j.
disamonth.2016.03.012
[14] Herbert LJ, Middleton SI. An estimate of syphilis incidence in Eastern Europe. Journal of 
Global Health. 2012;2:010402. DOI: 10.7189/jogh.02.010402
[15] Shockman S, Buescher LS, Stone SP. Syphilis in the United States. Clinics in Dermatology. 
2014;32:213‐218. DOI: 10.1016/j.clindermatol.2013.08.005
[16] Copeland NK, Decker CF. Other sexually transmitted diseases chancroid and donova-
nosis. Disease‐a‐month. 2016;62:306‐313. DOI: 10.1016/j.disamonth.2016.03.016
[17] Lewis DA, Mitjà O. Haemophilus ducreyi: From sexually transmitted infection to skin 
ulcer pathogen. Current Opinion in Infectious Diseases. 2016;29:52‐57. DOI: 10.1097/
QCO.0000000000000226
[18] Stary G, Stary A. Lymphogranuloma venereum outbreak in Europe. Journal der Deutschen 
Dermatologischen Gesellschaft. 2008;6:935‐940. DOI: 10.1111/j.1610‐0387.2008.06742.x
[19] Apers L, Crucitti T, Verbrugge R, Vandenbruaene M. Sexually transmitted infections: 
what’s new? Acta Clinica Belgica. 2012;67:154‐159
[20] Savage EJ, van de Laar MJ, Gallay A, van der Sande M, Hamouda O, Sasse A, et al. European 
surveillance of sexually transmitted infections (ESSTI) network. Lymphogranuloma 
venereum in Europe 2003‐2008. Eurosurveill. 2009;14(48):19428
[21] Hutter JN, Decker CF. Human papillomavirus infection. Disease‐a‐month. 2016;62:294‐
300. DOI: 10.1016/j.disamonth.2016.03.014
[22] Park IU, Introcaso C, Dunne EF. Human papillomavirus and genital warts: A review of 
the evidence for the 2015 centers for disease control and prevention sexually transmit-
ted diseases treatment guidelines. Clinical Infectious Diseases. 2015;61:S849‐S855. DOI: 
10.1093/cid/civ813
Introductory Chapter: The Latest Knowledge
http://dx.doi.org/10.5772/intechopen.69261
11
[23] Koren M, Decker CF. Genital herpes. Disease‐a‐month. 2016;62:287‐293. DOI: 10.1016/j.
disamonth.2016.03.013
[24] Sauerbrei A. Optimal management of genital herpes: Current perspectives. Infection 
and Drug Resistance. 2016;9:129‐141. DOI: 10.2147/IDR.S96164
[25] Wahid B, Ali A, Idrees M, Rafique S. Immunotherapeutic strategies for sexually trans-
mitted viral infections: HIV, HSV, and HPV. Cellular Immunology. 2016;310:1‐13. DOI: 
10.1016/j.cellimm.2016.08.001
[26] Decker CF. Emerging sexually transmitted diseases: Hepatitis C, lymphogranuloma 
venereum (LGV), and Mycoplasma genitalium infections. Disease‐a‐month. 2016;62:314‐
318. DOI: 10.1016/j.disamonth.2016.03.017.
[27] Meites E, Gaydos CA, Hobbs MM, Kissinger P, Nyirjesy P, Schwebke JR et al. A review 
of evidence‐based care of symptomatic trichomoniasis and asymptomatic trichomonas 
vaginalis infections. Clinical Infectious Diseases. 2015;61:S837‐848. DOI: 10.1093/cid/
civ738
[28] Mielczarek E, Blaszkowska J. Trichomonas vaginalis: Pathogenicity and potential role in 
human reproductive failure. Infection. 2016;44:447‐458. DOI: 10.1007/s15010‐015‐0860‐0
[29] Mohammed H, Hughes G, Fenton KA. Surveillance systems for sexually transmitted 
infections: A global review. Current Opinion in Infectious Diseases. 2016;29:64‐69. DOI: 
10.1097/QCO.0000000000000235
[30] Workowski KA, Berman S, Centers for Disease Control and Prevention (CDC). Sexually 
transmitted diseases treatment guidelines, 2010. MMWR Recommendations and Reports. 
2010;59:1‐110
[31] Fanfair RN, Workowski KA. Clinical update in sexually transmitted diseases‐2014. 
Cleveland Clinic Journal of Medicine. 2014;81:91‐101. DOI: 10.3949/ccjm.81a.13090
[32] Edwards JL, Jennings MP, Apicella MA, Seib KL. Is gonococcal disease preventable? 
The importance of understanding immunity and pathogenesis in vaccine development. 
Critical Reviews in Microbiology. 2016;42:928‐941. DOI: 10.3109/1040841X.2015.1105782
[33] Handler NS, Handler MZ, Majewski S, Schwartz RA. Human papillomavirus vaccine tri-
als and tribulations: Vaccine efficacy. Journal of the American Academy of Dermatology. 
2015;73:759‐767. DOI: 10.1016/j.jaad.2015.05.041
[34] Pitisuttithum P, Velicer C, Luxembourg A. 9‐Valent HPV vaccine for cancers, pre‐cancers 
and genital warts related to HPV. Expert Review of Vaccines. 2015;14:1405‐1419. DOI: 
10.1586/14760584.2015.1089174
[35] Shum J, Kelsberg G, Safranek S. Clinical Inquiry: Does qHPV vaccine prevent anal 
intraepithelial neoplasia and condylomata in men? The Journal of Family Practice. 
2015;64:581‐583
Fundamentals of Sexually Transmitted Infections12
[36] Ooi C, Lewis D. Updating the management of sexually transmitted infections. Australian 
Prescriber. 2015;38:204‐208.
[37] Van Howe RS. Sexually transmitted infections and male circumcision: A system-
atic review and meta‐analysis. International Scholarly Research Notices: Urology. 
2013;2013:109846. DOI: 10.1155/2013/109846
[38] Scott HM, Klausner JD. Sexually transmitted infections and pre‐exposure prophylaxis: 
Challenges and opportunities among men who have sex with men in the US. AIDS 
Research and Therapy. 2016;13:5. DOI: 10.1186/s12981‐016‐0089‐8
[39] Cairns G, McCormack S, Molina JM. The European preexposure prophylaxis revolution. 
Current Opinion in HIV and AIDS. 2016;11:74‐79. DOI: 10.1097/COH.0000000000000223
[40] Chan DP, Sun HY, Wong HT, Lee SS, Hung CC. Sexually acquired hepatitis C virus 
infection: A review. International Journal of Infectious Diseases. 2016;49:47‐58. DOI: 
10.1016/j.ijid.2016.05.030
[41] Tsevat DG, Wiesenfeld HC, Parks C, Peipert JF. Sexually transmitted diseases and 
infertility. American Journal of Obstetrics & Gynecology. 2017;216:1‐9. DOI: 10.1016/j.
ajog.2016.08.008
[42] Ortayli N, Ringheim K, Collins L, Sladden T. Sexually transmitted infections: progress 
and challenges since the 1994 international conference on population and development 
(ICPD). Contraception. 2014;90:S22‐S31. DOI: 10.1016/j.contraception.2014.06.024
[43] Rompalo A. Preventing sexually transmitted infections: Back to basics. Journal of Clinical 
Investigation. 2011;121:4580‐4583. DOI: 10.1172/JCI61592
[44] Rogstad KE, Wilkinson D, Robinson A. Sexually transmitted infections in children as 
a marker of child sexual abuse and direction of future research. Current Opinion in 
Infectious Diseases. 2016;29:41‐44. DOI: 10.1097/QCO.0000000000000233
[45] Seña AC, Hsu KK, Kellogg N, Girardet R, Christian CW, Linden J, et al. Sexual assault and 
sexually transmitted infections in adults, adolescents, and children. Clinical Infectious 
Diseases. 2015;61:S856‐864. DOI: 10.1093/cid/civ786
Introductory Chapter: The Latest Knowledge
http://dx.doi.org/10.5772/intechopen.69261
13

